✦ LIBER ✦

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group

✍ Scribed by Noortje Thielen, Bronno van der Holt, Gregor E. G. Verhoef…

Book ID: 120775792
Publisher: Springer
Year: 2013
Tongue: English
Weight: 275 KB
Volume: 92
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-013-1730-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-vs low-dose cytarabine combined wit

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study

✍ W. Deenik; B. van der Holt; G. E. G. Verhoef; A. V. M. B. Schattenberg; L. F. Ve 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 166 KB

Efficacy of imatinib dose escalation in

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

✍ Hagop M. Kantarjian; Richard A. Larson; Francois Guilhot; Stephen G. O'Brien; Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB 👁 3 views

Effects of the mean daily doses of imati

Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group

✍ Junichi Sugita; Junji Tanaka; Mitsutoshi Kurosawa; Takashi Fukuhara; Satoshi Has 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

A phase III comparison of high dose ARA-

A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia: Southwest Oncology Group Study

✍ Chatchada Karanes; Kenneth J Kopecky; David R Head; Michael R Grever; Harry E Hy 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Ofatumumab Combined With Fludarabine and

Ofatumumab Combined With Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Results From a Randomized, Multicenter, International, Two-Dose, Parallel-Group Phase II Trial

✍ William G. Wierda; Thomas J. Kipps; Jan Dürig; Laimonas Griskevicius; Stephan St 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 70 KB

Immune modulation of minimal residual di

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia : A randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor

✍ Jorge Cortes; Alfonso Quintás-Cardama; Dan Jones; Farhad Ravandi; Guillermo Garc 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB